Share
Publications
-
27 May 2013 /Prices and reimbursement
Monitor the trends in consumption of drugs for acid-related disorders
The Danish Medicines Agency monitors the consumption of drugs for acid-related disorders (drugs for heartburn, sour eructation and ulcer) in connection with the removal of the reimbursement for a number of these drugs on 15 November 2010.
-
15 April 2011 | Updated 27 May 2013 /Prices and reimbursement
Monitor the trends in consumption of cardiovascular medicines
We monitor the trends in consumption of cardiovascular medicines (blood pressure medicines) in connection with the reimbursement changes for cardiovascular medicines of 13 July 2009 and 15 November 2010.
-
16 May 2013 /Authorisation and supervision
Annual report 2011 on laboratory control activities
The medical authorities in Europe cooperate in a network called the Official Medicines Control Laboratories (OMCL). The Danish Medicines Agency has published an annual report for 2011 that describes the activities of the Agency to the OMCL network.
-
20 March 2013 /Side effects and trials
Adverse drug reaction reports (ADRs) from consumers may improve patient safety
In a report, the DHMA has reviewed the ADR reports received during the years 2003–2011 to clarify how consumer reports differ from reports from healthcare professionals.
-
07 December 2012 /Product areas
Annual report human on tissues and cells 2011
The annual report for human tissues and cells for 2011 has been prepared pursuant to the Danish Tissue Act and is based on reports submitted by tissue establishments and gynaecology clinics in Denmark in the period January to December 2011.
-
26 November 2012 /Authorisation and supervision
Product defects and withdrawal of medicines 2011
In 2011, 356 reports of medicinal product defects were registered, which is the highest number ever. The majority of the reports came from companies and other authorities and predominantly concerned defects on the package and packaging material and deviations from specifications.
-
12 November 2012 /Prices and reimbursement
-
12 November 2012 /Retail and online sale
-
01 August 2012 /Side effects and trials
Danish Medicines Agency's annual pharmacovigilance report 2011
The annual pharmacovigilance report offers an insight into some of the pharmacovigilance work performed by the Danish Medicines Agency in 2011.
-
02 March 2012 /Prices and reimbursement
Number of applications for individual reimbursement of medicines in 2011
In 2011, the Danish Medicines Agency (now the Danish National Board of Health) reviewed approx. 103,000 applications for single reimbursement (about 7 % more than in 2010), approx. 26,000 applications for reimbursement for the chronically ill (about 30 % less than in 2010), approx. 12,000 applications for reimbursement for the terminally ill (about 3 % more than in 2010) and approx. 2,500 applications for increased reimbursement (about 12 % less than in 2010), cf. table 1.
-
31 January 2012 /Side effects and trials
Long-term treatment of osteoporosis patients with bisphosphonates
At present, there is very limited knowledge about long-term treatment with bisphosphonates for osteoporosis patients. But over the past years, reports suggestive of long-term adverse reactions have been submitted, e.g. osteonecrosis of the jaw and atypical fractures.
-
20 January 2005 | Updated 21 November 2011 /Publications - miscellaneous
From old industrial plant to open workspace
The Danish Medicines Agency's introductory leaflet about the transformation from old soya bean cake factory into a streamlined modern workplace. From old industrial plant to open workspace.
-
17 February 2005 | Updated 04 November 2011 /Prices and reimbursement
Decreasing consumption of Zyprexa®
The consumption of the antipsychotic medicinal product Zyprexa® decreased during 2004. The decrease in consumption has taken place following EMEA's announcement in March 2004 about a heightened risk of death and brain haemorrhage from treating elderly dementia patients with Zyprexa®.
-
28 October 2011 /Product areas
Annual report on human tissues and cells 2010
The annual report for human tissues and cells for 2010 has been prepared pursuant to the Danish Tissue Act and is based on reports submitted by tissue establishments and gynaecology clinics in Denmark in the period January to December 2010.
-
12 October 2011 /Side effects and trials
Publication on medicines most frequently involved in serious adverse drug events
A new study carried out by a working group associated with the Danish Medicines Agency's network "Prevention of Medication Errors" has shown that it is more or less the same groups of medicines that have been involved in the so-called adverse events from the 1970s and up until today. Based on the study, we have drawn up two lists of medicines that appear in high-risk situations – sorted by active substance and medicine group. The Danish Medicines Agency and the working group behind the study hope that these lists can become an important tool in the daily work with risks in the medication process in the health sector.
-
12 September 2011 /Authorisation and supervision
Product defects and withdrawal of medicines 2010
In 2010, the Danish Medicines Agency received a total of 262 reports on product defects involving medicines. This is the highest number of reports received within the past five years.
-
24 August 2011 /Retail and online sale
Annual report on the inspection of retail sale of OTC medicines 2009-2010
In our report for 2008-2009, we made a number of critical remarks about the pharmacies' OTC outlets where we found too many deficiencies: expired medicines, possibility of self-service, medicines mixed with other goods, staff which did not know the rules, etc.
-
12 August 2011 /Product areas
Report on the blood product area in 2010
In 2010, 337.000 blood collections were made in Denmark. This is approximately 21.000 collections less than the previous year. Moreover, approximately 317.000 units of red blood cells (erythrocytes) were used in connection with blood transfusions in 2010.
-
22 July 2011 /Authorisation and supervision
Annual report 2010 of the Danish Medicines Agency's laboratory control activities
he drug regulatory authorities in Europe cooperate in a network called the Official Medicines Control Laboratories (OMCL). The Danish Medicines Agency has published an annual report for 2010 that describes the activities of the Agency to the OMCL network.
-
20 June 2011 /Side effects and trials
Danish Medicines Agency’s annual pharmacovigilance report 2010
In 2010, primarily the Danish Minister for the Interior and Health’s action plan to improve monitoring of side effects marked the work in the pharmacovigilance area. The action plan was launched in 2009 in cooperation with the Council for Adverse Drug Reactions and was fully implemented in 2010. The annual report offers an insight into much of the pharmacovigilance work performed by the Danish Medicines Agency in 2010.
